ARWR

41.3705.22%
RG

Robert G. Gish

Chairman of Hepatitis B Clinical Advisory Board

Dr. Robert G. Gish, M.D. serves as Member of Clinical Advisory Board at HepaTx Corporation since July 2023. He was Member of Scientific Advisory Board at HepaTx Corp. since November 2021 until July 2023. He is the Co-Principal Investigator of ETHECC(C) Trial at YM BioSciences USA Inc. since April 2004. Dr. Gish serves as Chief of Clinical Hepatology, Professor of Clinical Medicine and co-director of the Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT) at the University of California, San Diego School of Medicine. Dr. Gish serves as Medical Director of the Liver Transplant Program at California Pacific Medical Center in San Francisco. He serves as the Chairman of Hepatitis B Clinical Advisory Board at Arrowhead Pharmaceuticals, Inc. (formerly known as Arrowhead Research Corp.) He serves as Member of Advisory Board of HepaHope, Inc. He served as Member of ClinicalAdvisory Board at Apricus Biosciences, Inc., since October 2010. He served as Member of Hepatitis C Advisory Board at Exagen Diagnostics, Inc. Dr. Gish has co-authored five communications on THYMITAQ(R) and the ETHECC(C) trial and has presented scientific posters at the 2003 Annual Meeting of the American Association for the Study of Liver Diseases and at the 2004 Hong Kong-Shanghai International Liver Congress. He is board certified in Internal Medicine and Gastroenterology and has the advance Certificate of Added Qualification (CAQ) in Liver Transplantation and is a UNOS certified Liver Transplant Physician. Dr. Gish received his Medical Degree from the University of Kansas in Kansas City. He completed his internship and residency in internal medicine at the University of California, San Diego School of Medicine and a fellowship in Gastroenterology and Hepatology at the University of California, Los Angeles.

公司职务